drugset / Trial / NCT05458856

Effects of Triptorelin When Given Every 6-months Under the Skin to Adult Males With Cancer in the Prostate

NCT05458856

Phase 3 Completed 147 enrolled Ipsen
NaSingle-groupOpen-labelTreatment

Summary

The aim of the study is to determine if triptorelin formulated for use every 6 months (given twice during the study) is effective and safe for when given by injection under the skin for the treatment of adult males with cancer in the prostate.

Timeline

Start
2022-08-30
Primary completion
2024-07-08
Completion
2024-07-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Triptorelin Other / unclassified 22.5 mg Subcutaneous

Indications